Free Trial
NASDAQ:SHPG

Shire (SHPG) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.20
$179.20
50-Day Range
$179.20
$179.20
52-Week Range
$123.73
$182.47
Volume
N/A
Average Volume
2.21 million shs
Market Capitalization
$54.71 billion
P/E Ratio
11.83
Dividend Yield
0.19%
Price Target
N/A
SHPG stock logo

About Shire Stock (NASDAQ:SHPG)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

SHPG Stock News Headlines

SHPG Historical Data
Shire Stock Hits New 52-Week High (SHPG)
How did they achieve a perfect track record?
If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...
How did they achieve a perfect track record?
If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...
Amanda Shires : Fresh Air - NPR
Amanda Shires - Take It Like A Man - Country Standard Time
See More Headlines
Receive SHPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/26/2018
Today
7/15/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SHPG
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$4.27 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.16 billion
Cash Flow
$22.71 per share
Book Value
$119.43 per share

Miscellaneous

Free Float
N/A
Market Cap
$54.71 billion
Optionable
Optionable
Beta
0.87
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


SHPG Stock Analysis - Frequently Asked Questions

How were Shire's earnings last quarter?

Shire plc (NASDAQ:SHPG) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, topping analysts' consensus estimates of $3.58 by $0.28. The firm's quarterly revenue was up 5.4% compared to the same quarter last year.

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS) and Johnson & Johnson (JNJ).

This page (NASDAQ:SHPG) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners